Author:
Jong-van den Berg Lolkje,Mintzes Barbara
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmaceutical Science,Pharmacology,Toxicology,Pharmacy,General Medicine,Pharmacology (medical),Pharmacology
Reference13 articles.
1. Herings RMC, Stricker BHC. Bromocriptine and suppression of postpartum lactation. The incidence of adverse cardiovascular effects in women of child-bearing age. Pharm World Sci 1995;17:133–7.
2. US Food and Drug Administration. Sandoz Pharmaceutical Corp.: Bromocriptine mesylate (Parlodel); withdrawal of approval of the indication for the prevention of physiological lactation. Fed Reg 1995;60:3404–5.
3. Health Canada, Drugs Directorate. Bromocriptine and lactation suppression. Can Adverse Drug React Newsletter 1995;5:66–7.
4. US Food and Drug Administration. Sandoz Pharmaceutical Corp.: Bromocriptine mesylate (Parlodel) for the prevention of physiological lactation; opportunity for a hearing on a proposal to withdraw of approval of the indication. Fed Reg 1994;59:43347–52.
5. McCarthy M. Bromocriptine not for lactation suppression. Lancet 1994;344:602.
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献